Portfolio Management and Disease Area Strategy
How does a firm set disease area strategy to maximize their portfolio value? With a heavy focus on clinical development, early stage platform companies often postpone addressing this challenge. Meanwhile, the largest companies in the industry struggle to further improve their portfolio management. Our firm has unique and extensive experience in portfolio management, portfolio reviews, and portfolio management system design and implementation from both perspectives. As a result we ask the right questions and make the correct tradeoffs, earning us the trust and ability to develop disease area strategies for Big 10 pharma and successfully prioritize the pipelines of some of the most exciting technology platforms in biotech.